CTLA-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice

Journal of Immunotherapy

Volumn 38, Issue 2, 2015, Pages 54-61

  Mahvi, David A ^a   Meyers, Justin V ^a   Tatar, Andrew J ^a   Contreras, Amanda ^a   Suresh, Marulasiddappa ^b   Leverson, Glen E ^a   Sen, Siddhartha ^a   Cho, Clifford S ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

adoptive cell transfer; cancer; CTLA 4; immunotherapy; melanoma; T cell

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CTLA 4; PROTEIN GP33; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN; GLYCOPROTEIN; GLYCOPROTEIN PEPTIDE 33-41, LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PEPTIDE FRAGMENT; VIRAL PROTEIN; VIRUS ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CANCER TRANSPLANTATION; CELLULAR IMMUNITY; DISEASE MODEL; EXPERIMENTAL MELANOMA; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; SKIN TUMOR; TRANSGENE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, VIRAL; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; SKIN NEOPLASMS; T-LYMPHOCYTES; TRANSGENES; TUMOR BURDEN; VIRAL PROTEINS;

EID: 84922718852     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000064     Document Type: Article

References (23)

1. Rosenberg SA, Yannelli JR, Yang JC, et al Treatment of patients with metastatic melanoma with autologous tumorinfiltrating lymphocytes and interleukin 2 J Natl Cancer Inst. 1994;86:1159-1166.
2. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550-4557.
3. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
4. Fisher B, Packard BS, Read EJ, et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol. 1989;7:250-261.
5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
6. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039-2047.
7. Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119:1675-1682.
8. Fecher LA, Agarwala SS, Hodi FS, et al. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013;18:733-743.
9. Wentworth L, Meyers JV, Alam S, et al. Memory T cells are uniquely resistant to melanoma-induced suppression. Cancer Immunol Immunother. 2013;62:149-159.
10. Russ AJ, Wentworth L, Xu K, et al. Suppression of T-cell expansion by melanoma is exerted on resting cells. Ann Surg Oncol. 2011;18:3848-3857.
11. Russ AJ, Xu K, Wentworth L, et al. Melanoma-induced suppression of tumor antigen-specific T cell expansion is comparable to suppression of global T cell expansion. Cell Immunol. 2011;271:104-109.
12. Murali-Krishna K, Altman JD, Suresh M, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 1998;8:177-187.
13. Parviz M, Chin CS, Graham LJ, et al. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol Immunother. 2003;52:739-750.
14. Le HK, Graham L, Miller CH, et al. Incubation of antigensensitized T lymphocytes activated with bryostatin 1+ionomycin in IL-7+IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol Immunother. 2009;58:1565-1576.
15. Miller CH, Graham L, Bear HD. Phenotype, functions and fate of adoptively transferred tumor-draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma. BMC Immunol. 2010;11:54.
16. Li N, Qin H, Li X, et al. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model. Immunol Lett. 2007;113:90-98.
17. Watanabe A, Hara M, Chosa E, et al. Combination of adoptive cell transfer and antibody injection can eradicate established tumors in mice - an in vivo study using anti-OX40 mAb, anti-CD25 mAb and anti-CTLA4 mAb. Immunopharm Immunotoxicol. 2010;32:238-245.
18. Shin JH, Park HB, Oh YM, et al. Positive conversion of negative signaling of CTLA-4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. Blood. 2012;119:5678-5687.
19. Berrien-Elliott MM, Jackson SR, Meyer JM, et al. Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res. 2012;73:605-616.
20. Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009;15:6267-6276.
21. Besser MJ, Shapira-Frommer R, Itzhaki O, et al. Adoptive transfer of tumor infiltrating lymphocytes in metastatic melanoma patients: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res. 2013;19:4792-4800.
22. Hamid O, Schmidt H, Nissan A, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204.
23. Tarhini AA, Edington H, Butterfield LH, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9:e87705.